Angiopoietin-like proteins - their role in lipoprotein metabolism and association with atherogenic dyslipidemia

Abstract

Scientists have been trying to find the best parameter for laboratory assessment of the risk of cardiovascular diseases (CVD) for decades. Initially, the results of many studies indicated that the analysis of the lipid profile was sufficient to evaluate the risk of CVD. Further studies revealed that more precise laboratory prediction of cardiovascular risk requires quantification of atherogenic lipoproteins. Recently, angiopoietin-like proteins 3, 4 and 8 (ANGPTLs) have been described as important regulators of plasma lipoprotein metabolism and triglyceride homeostasis. Mutations in ANGPTL3 leading to loss of its function have been linked to decreased risk of CVD in humans. Among potential new targets for the management of dyslipidemia, ANGPTL3 may become a considerably promising one.